Key result
Monoclonal antibodies RR5.ET-1 and RR1.ET-1 specifically bind the carboxyl-terminus of endothelin-1, requiring a free terminal Trp21 for reactivity.
The study successfully developed and characterized monoclonal antibodies specific to the carboxyl-terminal of endothelin-1, which require a free terminal Trp21 for binding.
Two cell lines, RR5.ET-1 and RR1.ET-1, that produce monoclonal antibodies specific for the carboxyl-terminal heptapeptide of endothelin-1 (ET-1) have been cloned and stabilized. An RIA was developed to facilitate the evaluation and characterization of these monoclonal antibodies. The affinity constant of each MAb for ET-1, as determined by Scatchard analysis, was 5.74 x 10(8) M-1 for RR5.ET-1 and 4.15 x 10(7) M-1 for RR1.ET-1. The antibodies reacted specifically with the carboxyl-terminus (ET15-21) and did not cross-react with the amino-terminal amino acids (ET1-16). As expected, the antibodies cross-reacted with endothelin-2 (ET-2) and endothelin-3 (ET-3), and to a lesser extent, with the closely related sarafotoxins. Both MAbs retained about 55% reactivity with the ET-1 terminal sequence of Asp-Ile-Ile-Trp (ET18-21) but had no reactivity with the ET sequence His-Leu-Asp-Ile-Ile-Trp-Val-Asn (ET16-23) nor with Big ET-1 (ET1-39). These data strongly suggest that the terminal four amino acids of ET-1 are included in the MAb binding site. More importantly, the terminal Trp21 must be free, not linked to Val22 to retain reactivity with either of the MAbs.
No takes yet. Share an insight, caveat, or question.
Frosco et al. (1993) studied this question. Monoclonal antibodies to the carboxyl-terminal heptapeptide of endothelin-1 (RR5.ET-1 and RR1.ET-1) was evaluated on Affinity constant and cross-reactivity. Monoclonal antibodies RR5.ET-1 and RR1.ET-1 specifically bind the carboxyl-terminus of endothelin-1, requiring a free terminal Trp21 for reactivity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: